MENU

Clinical Trials

Arkansas Children’s, we are connected to international networks of researchers studying and developing the latest medical therapies. In many cases, we can provide treatments to your child right here on campus. In some cases, we may connect your child to developing treatments based at a partner medical center. To learn more about participating in a clinical trial, check out our Frequently Asked Questions.

  • Ewing Sarcoma at First Relapse sponsored by Gardalis – A Multi-Center Phase 3, Randomized, Open-Label Trial of Vigil (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in combination with Irinotecan and Temozolomide as a Second-Line Regimen for Ewing Sarcoma
  • High-Risk Neuroblastoma at Initial Diagnosis sponsored by The Beat Childhood Cancer Consortium - PEDS-PLAN (Pediatric Precision Laboratory Advanced Neuroblastoma Therapy) A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma
  • Relapsed or Refractory Solid Tumors and Leukemia sponsored by Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) -  A phase I study of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
  • High-Risk Hodgkin’s Lymphoma at Initial Diagnosis sponsored by Takeda - An Open-Label Study of Brentuximab Vedotin+Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
  • Relapsed, Refractory, or Treatment-Naïve Severe Aplastic Anemia sponsored by Novartis -  A phase II, open-label, non-controlled, intra-patient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, relapsed or treatment naïve severe aplastic anemia or recurrent aplastic anemia
  • Neuroblastoma in First Remission sponsored by The Beat Childhood Cancer Consortium - NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
  • The pan-ERBB inhibitor Neratinib in Previously Treated Solid and Brain Tumors sponsored by Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) – a Phase I Study for recurrent or refractory solid and brain tumors including:
  • MEK Inhibitor Cobimetnib in Previously Treated Solid Tumors (Study G029665) sponsored by Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) – a Phase 2 Study for Low-Grade Gliomas